Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First in-human trial of M102 in patients with the neurodegenerative disease

X
Trial Profile

First in-human trial of M102 in patients with the neurodegenerative disease

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 22 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apomorphine (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 20 Apr 2022 According to an Aclipse Therapeutics media release, the trial is expected to initiate in 2023
    • 20 Apr 2022 According to an Aclipse Therapeutics media release, the Company has received a therapeutic development award from the Congressionally Directed Medical Research Programs at the United States Department of Defense's U.S. Army Medical Research and Development Command, as part of its FY21 Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award. The award will fund development of M102 to Investigational New Drug (IND) Stage for Initiation of this trial.
    • 08 Feb 2021 According to a University of Sheffield media release, the company has received research grant which will be used for this study.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top